Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pediatric acute lymphoblastic leukemia (ALL) remains challenging for subsets of patients refractory to current treatments.
• Novel therapeutic targets are crucial for improving outcomes in relapsed or refractory pediatric ALL.
• Survivin, an inhibitor of apoptosis protein, is implicated in various cancers.

Purpose of the Study:

• To investigate survivin as a potential therapeutic target in pediatric acute lymphoblastic leukemia (ALL).
• To evaluate the efficacy of survivin silencing and inhibition in reducing pediatric ALL cell viability.
• To explore the role of p53-dependent apoptosis in survivin-targeted therapy.

Main Methods:

• Utilized RNA interference technology to silence survivin expression in pediatric ALL cell lines and primary leukemic blasts.
• Assessed the impact of survivin silencing on cell viability and apoptosis.
• Investigated the role of p53 in survivin inhibition-induced apoptosis.
• Screened survivin-specific small interfering RNA (siRNA) and the drug YM155 in primary patient samples.

Main Results:

• Survivin was uniformly overexpressed in multiple pediatric ALL cell lines, including those with diverse cytogenetic abnormalities.
• Silencing survivin significantly reduced the viability of pediatric ALL cell lines and primary leukemic blasts.
• Inhibition of survivin enhanced p53-dependent apoptosis, which could be reversed by p53 inhibition.
• Survivin-specific siRNA and YM155 effectively reduced leukemic blast viability in primary patient samples.

Conclusions:

• Survivin is a promising therapeutic target for pediatric acute lymphoblastic leukemia (ALL).
• Targeting survivin, via siRNA or YM155, demonstrates significant anti-leukemic effects.
• Survivin inhibition represents a potential strategy to overcome chemotherapy resistance in pediatric ALL.